摘要
目的:观察安金理肺汤治疗小儿咳嗽变异性哮喘的临床疗效。方法:将94例患儿随机分为治疗组54例对照组40例,治疗组用安金理肺汤口服,对照组用布地奈德、沙丁胺醇气雾剂吸入治疗,治疗4周,分别在治疗程结束、停药2周时评价总体疗效及血清嗜酸细胞阳离子蛋白(ECP)浓度的变化。结果:治疗组和对照组治疗四周,总体疗效和ECP水平差异无统计学意义(P>0.05)。停药两周后治疗组疗效优于对照组,且ECP水平明显低于对照组,两组差异有统计学意义(P<0.05)。说明安金理肺汤治疗CVA疗效与吸入布地奈德、硫酸沙丁胺醇气雾剂疗效相当,但作用更持久。
Objective： To observe the clinical efficacy of treating CVA in children with the Anjin Lifei decoction. Methods： 94 patients were randomly divided into treatment group （54 cases） and control group （40 cases）, the treatment group treated with the Anjin Lifei decoction, and control group was given budesonide, albuterol aerosol for treatment, 4 weeks of treatment, respectively, in the treatment of end, stopping for two weeks to evaluate the overall efficacy and serum eosinophil cationic protein （ECP） concentration changes. Results： After four weeks of treatment, the overall efficacy of the treatment group and control group and ECP level difference not statistically significant （P〉0.05）. Stop the medication two weeks after the treatment group than the control group, and the ECP level was significantly lower than the control group, the difference was statistically significant （P〈0.05）. Treating CVA with the Anjin Lifei decoction efficacy of inhaled budesonide, salbutamol sulfate aerosol efficacy, but the effect is more durable.
出处
《中医临床研究》
2012年第17期22-23,共2页
Clinical Journal Of Chinese Medicine
